Molecular Insight Pharma Inc. (MIPI) reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra. The company said the study demonstrated a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma.
The study was designed to evaluate the safety and identify the maximum tolerated dose of Azedra, as well as to collect clinical data on efficacy. In the 12-month data reported, a single dose of Azedra was shown to be well tolerated by patients, and toxicities were predictable and manageable. Azedra demonstrated clinical benefit, stabilizing or reducing tumor volumes in a majority of patients.
For comments and feedback: editorial@rttnews.com